Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Low-Dose Naltrexone (LDN)—Review of Therapeutic Utilization
Karlo Toljan, Bruce Vrooman
Medical Sciences (2018) Vol. 6, Iss. 4, pp. 82-82
Open Access | Times Cited: 120

Showing 1-25 of 120 citing articles:

Chronic pain: an update on burden, best practices, and new advances
Steven P. Cohen, Lene Vase, W. Michael Hooten
The Lancet (2021) Vol. 397, Iss. 10289, pp. 2082-2097
Closed Access | Times Cited: 1463
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation
Roger S. McIntyre, Joshua D. Rosenblat, Charles B. Nemeroff, et al.
American Journal of Psychiatry (2021) Vol. 178, Iss. 5, pp. 383-399
Open Access | Times Cited: 468
Low-dose naltrexone and NAD+ for the treatment of patients with persistent fatigue symptoms after COVID-19
Anar Isman, Andy Nyquist, Bailey Strecker, et al.
Brain Behavior & Immunity - Health (2024) Vol. 36, pp. 100733-100733
Open Access | Times Cited: 14
Milestones in the journey towards addressing obesity; Past trials and triumphs, recent breakthroughs, and an exciting future in the era of emerging effective medical therapies and integration of effective medical therapies with metabolic surgery
Michail Kokkorakis, Angeliki Katsarou, Niki Katsiki, et al.
Metabolism (2023) Vol. 148, pp. 155689-155689
Open Access | Times Cited: 21
Cancer Metabolism as a Therapeutic Target and Review of Interventions
Matthew Halma, Jack A. Tuszyński, Paul E. Marik
Nutrients (2023) Vol. 15, Iss. 19, pp. 4245-4245
Open Access | Times Cited: 19
The Safety and Efficacy of Low-Dose Naltrexone in Patients with Fibromyalgia: A Systematic Review
Juan Yang, Kyung-Min Shin, Alex Do, et al.
Journal of Pain Research (2023) Vol. Volume 16, pp. 1017-1023
Open Access | Times Cited: 16
Effective Doses of Low-Dose Naltrexone for Chronic Pain – An Observational Study
Norman J. Marcus, Lexi Robbins, Aya Araki, et al.
Journal of Pain Research (2024) Vol. Volume 17, pp. 1273-1284
Open Access | Times Cited: 6
Low-dose naltrexone for post-COVID fatigue syndrome: a study protocol for a double-blind, randomised trial in British Columbia
Hiten Naik, Erin Cooke, Travis Boulter, et al.
BMJ Open (2024) Vol. 14, Iss. 5, pp. e085272-e085272
Open Access | Times Cited: 6
The uses of naltrexone in dermatologic conditions
Brigette Lee, Dirk M. Elston
Journal of the American Academy of Dermatology (2018) Vol. 80, Iss. 6, pp. 1746-1752
Closed Access | Times Cited: 52
Opioid system influences gut-brain axis: Dysbiosis and related alterations
Lola Rueda‐Ruzafa, Francisco Cruz, Diana Cardona, et al.
Pharmacological Research (2020) Vol. 159, pp. 104928-104928
Closed Access | Times Cited: 44
Low-dose naltrexone as a treatment for chronic fatigue syndrome
Monica Bolton, Bryan Paul Chapman, Harm van Marwijk
BMJ Case Reports (2020) Vol. 13, Iss. 1, pp. e232502-e232502
Open Access | Times Cited: 42
Immunometabolic Modulatory Role of Naltrexone in BV-2 Microglia Cells
Natalia Kučić, Valentino Rački, Roberta Šverko, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 16, pp. 8429-8429
Open Access | Times Cited: 34
The Stress Phenotyping Framework: A multidisciplinary biobehavioral approach for assessing and therapeutically targeting maladaptive stress physiology
Rachel Gilgoff, Summer Mengelkoch, Jorina Elbers, et al.
Stress (2024) Vol. 27, Iss. 1
Open Access | Times Cited: 5
Neuropathic pain management: a focused review of current treatments and novel data from main ongoing clinical trials
Nikola Andrejić, Ivo Božović, Hadi Moradi, et al.
Expert Opinion on Investigational Drugs (2025)
Closed Access
The Effects of Low Dose Naltrexone on Opioid Induced Hyperalgesia and Fibromyalgia
Daniel Jackson, Sunita Singh, Yanli Zhang‐James, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 30
Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment
Hélène Cabanas, Katsuhiko Muraki, Natalie Eaton-Fitch, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 29
Repurposing low-dose naltrexone for the prevention and treatment of immunothrombosis in COVID-19
Bertram Pitt, Ashley M. Tate, David Gluck, et al.
European Heart Journal - Cardiovascular Pharmacotherapy (2022) Vol. 8, Iss. 4, pp. 402-405
Open Access | Times Cited: 19
Efficacy of Low-Dose Naltrexone and Predictors of Treatment Success or Discontinuation in Fibromyalgia and Other Chronic Pain Conditions: A Fourteen-Year, Enterprise-Wide Retrospective Analysis
Christine Driver, Ryan S. D’Souza
Biomedicines (2023) Vol. 11, Iss. 4, pp. 1087-1087
Open Access | Times Cited: 11
Low-dose naltrexone use for the management of post-acute sequelae of COVID-19
Hector Bonilla, Lü Tian, Vincent C. Marconi, et al.
International Immunopharmacology (2023) Vol. 124, pp. 110966-110966
Open Access | Times Cited: 11
Current and Evolving Concepts in the Management of Complex Regional Pain Syndrome: A Narrative Review
Burcu Candan, Semih Güngör
Diagnostics (2025) Vol. 15, Iss. 3, pp. 353-353
Open Access
Naltrexone Restores Impaired Transient Receptor Potential Melastatin 3 Ion Channel Function in Natural Killer Cells From Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients
Hélène Cabanas, Katsuhiko Muraki, Donald Staines, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 33
Naltrexone a potential therapeutic candidate for COVID-19
Abhinav Choubey, Budheswar Dehury, Sunil Kumar, et al.
Journal of Biomolecular Structure and Dynamics (2020) Vol. 40, Iss. 3, pp. 963-970
Open Access | Times Cited: 29
Low-dose naltrexone is effective and well-tolerated for modulating symptoms in patients with neuropathic corneal pain
G. Dieckmann, Mehmet Cüneyt Özmen, Stephanie Cox, et al.
The Ocular Surface (2021) Vol. 20, pp. 33-38
Open Access | Times Cited: 26
Low-dose naltrexone’s utility for non-cancer centralized pain conditions: a scoping review
Adam Rupp, Erin E. Young, Andrea L. Chadwick
Pain Medicine (2023) Vol. 24, Iss. 11, pp. 1270-1281
Open Access | Times Cited: 10
Understanding, diagnosing, and treating Myalgic encephalomyelitis/chronic fatigue syndrome – State of the art: Report of the 2nd international meeting at the Charité Fatigue Center
Sophie Steiner, Annick Fehrer, Friederike Hoheisel, et al.
Autoimmunity Reviews (2023) Vol. 22, Iss. 11, pp. 103452-103452
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top